Testosterone Therapy for Hypogonadism May Cut Risk for CV Events
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
Hypogonadism
COVID-19 Is Associated With Low Testosterone in Men
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
Kyzatrex Under Review for Primary and Secondary Male Hypogonadism
Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.
New Drug Product: Jatenzo
This slideshow shows drug information for Jatenzo. Click here for the complete Jatenzo monograph.
MPR Weekly Dose Podcast Episode 21
This week on the Pod we cover an insulin pump recall; Pharmacies running out of supplies in light of Covid-19 fears; Investigational Alzheimer disease treatments not meeting trial end points; A new cardiac ultrasound device; and a new oral testosterone replacement therapy.
Jatenzo, an Oral Testosterone Replacement Therapy, Now Available
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
Folic Acid, Zinc Supplements in Men No Benefit in Infertility
No significant improvement seen in semen quality, live births among couples seeking infertility treatment
Guideline Issued for Testosterone Therapy in Adult Men
Testosterone recommended for men with sexual dysfunction who want to improve sexual function.
Testosterone Therapy Tied to Increase in Short-Term VTE Risk
Among men with and without hypogonadism, testosterone therapy linked to elevated VTE risk
FDA Again Rejects NDA for Oral Testosterone Product Candidate
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Lipocine regarding the New Drug Application for Tlando (testosterone undecanoate), an oral testosterone product candidate for testosterone replacement therapy in adult males with primary hypogonadism or hypogonadotropic hypogonadism. In the CRL, the Agency noted that the trial establishing the efficacy of…
